5azz: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
The | ==Crystal structure of seleno-insulin== | ||
<StructureSection load='5azz' size='340' side='right' caption='[[5azz]], [[Resolution|resolution]] 1.45Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[5azz]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5AZZ OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5AZZ FirstGlance]. <br> | |||
</td></tr><tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5azz FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5azz OCA], [http://pdbe.org/5azz PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5azz RCSB], [http://www.ebi.ac.uk/pdbsum/5azz PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5azz ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[[http://www.uniprot.org/uniprot/INS_BOVIN INS_BOVIN]] Insulin decreases blood glucose concentration. It increases cell permeability to monosaccharides, amino acids and fatty acids. It accelerates glycolysis, the pentose phosphate cycle, and glycogen synthesis in liver. | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Synthetic insulin analogues with a long lifetime are current drug targets for the therapy of diabetic patients. The replacement of the interchain disulfide with a diselenide bridge, which is more resistant to reduction and internal bond rotation, can enhance the lifetime of insulin in the presence of the insulin-degrading enzyme (IDE) without impairing the hormonal function. The [C7UA ,C7UB ] variant of bovine pancreatic insulin (BPIns) was successfully prepared by using two selenocysteine peptides (i.e., the C7U analogues of A- and B-chains, respectively). In a buffer solution at pH 10 they spontaneously assembled under thermodynamic control to the correct insulin fold. The selenoinsulin (Se-Ins) exhibited a bioactivity comparable to that of BPIns. Interestingly, degradation of Se-Ins with IDE was significantly decelerated (tau1/2 approximately 8 h vs. approximately 1 h for BPIns). The lifetime enhancement could be due to both the intrinsic stability of the diselenide bond and local conformational changes induced by the substitution. | |||
Preparation of Selenoinsulin as a Long-Lasting Insulin Analogue.,Arai K, Takei T, Okumura M, Watanabe S, Amagai Y, Asahina Y, Moroder L, Hojo H, Inaba K, Iwaoka M Angew Chem Int Ed Engl. 2017 May 8;56(20):5522-5526. doi: 10.1002/anie.201701654., Epub 2017 Apr 10. PMID:28394477<ref>PMID:28394477</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
<div class="pdbe-citations 5azz" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Arai, K]] | [[Category: Arai, K]] | ||
[[Category: Asahina, Y]] | [[Category: Asahina, Y]] | ||
[[Category: Hojo, H]] | [[Category: Hojo, H]] | ||
[[Category: | [[Category: Inaba, K]] | ||
[[Category: Iwaoka, M]] | [[Category: Iwaoka, M]] | ||
[[Category: Okumura, M]] | [[Category: Okumura, M]] | ||
[[Category: Takei, T]] | |||
[[Category: Watanabe, S]] | |||
[[Category: Hormone]] | |||
[[Category: Insulin]] | |||
[[Category: Selenocysteine]] |